Solventum said it completed the sale of its Purification and Filtration business to Thermo Fisher Scientific Inc. on September 1, 2025, and that the cash consideration paid to the company at closing was approximately $4 billion.

10-KAnnual reportFiled Feb 27, 2026Period of report Dec 31, 2025Summary published (UTC) Oct 2, 2026

Key points

AI summary

Solventum said it completed the sale of its Purification and Filtration business to Thermo Fisher Scientific Inc. on September 1, 2025, and that the cash consideration paid to the company at closing was approximately $4 billion.
Solventum said it recognized a gain on sale of business of $1.5 billion in net income for 2025. After the sale closed, it used a tender offer to repurchase $2.0 billion of senior notes and repaid $870 million of principal on its 3-year term loan.
The company said the ratio of product costs to product sales increased in 2025 compared with 2024. It cited the impact of new tariffs of approximately $55 million, the full-year impact of inventory sourced under its supply and transition manufacturing agreements with 3M, and higher logistics costs as factors.
Solventum said it had cash and cash equivalents of $878 million as of December 31, 2025, of which approximately $800 million was held by its foreign subsidiaries. It said net cash provided by operating activities decreased in 2025 compared with 2024, and cited 3M separation costs and higher transaction-related activity as factors.

Key figures

Fiscal year ended December 31, 2025

Revenue: $8.3B
Operating income: $2.2B
Net income: $1.6B
EPS: $8.88
Gross profit: $4.5B
Operating cash flow: $369M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Completion of Purification and Filtration Sale and Approximately $4 billion in Proceeds

Solventum said it completed the sale of its Purification and Filtration business to Thermo Fisher Scientific Inc. on September 1, 2025, and that the cash consideration paid to the company at closing was approximately $4 billion.

Source · Based on the MD&A text of the filing

Gain on Business Sale of $1.5 billion and Debt Repayment

Solventum said it recognized a gain on sale of business of $1.5 billion in net income for 2025. After the sale closed, it used a tender offer to repurchase $2.0 billion of senior notes and repaid $870 million of principal on its 3-year term loan.

Source · Based on the MD&A text of the filing

Higher Cost of Product Sales and Tariff Costs in 2025

The company said the ratio of product costs to product sales increased in 2025 compared with 2024. It cited the impact of new tariffs of approximately $55 million, the full-year impact of inventory sourced under its supply and transition manufacturing agreements with 3M, and higher logistics costs as factors.

Source · Based on the MD&A text of the filing

Cash and Cash Equivalents of $878 million at End of 2025 and Lower Operating Cash Flow

Solventum said it had cash and cash equivalents of $878 million as of December 31, 2025, of which approximately $800 million was held by its foreign subsidiaries. It said net cash provided by operating activities decreased in 2025 compared with 2024, and cited 3M separation costs and higher transaction-related activity as factors.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.